The global Omalizumab Injection market size is predicted to grow from US$ 5246 million in 2025 to US$ 8036 million in 2032; it is expected to grow at a CAGR of 6.4% from 2026 to 2032.

Omalizumab injection is a targeted biological agent. It is a humanized monoclonal antibody that can precisely bind to and block immunoglobulin E (IgE), thereby preventing the release of inflammatory mediators such as histamine. It is often used to treat allergic asthma and chronic spontaneous urticaria (CSU) that do not respond well to traditional drugs (such as antihistamines), allowing patients to get rid of the troubles caused by allergic reactions and improve their quality of life.

Global production of omalizumab injection is projected to reach 7.15 million vials by 2025, with an average price of $750 per vial. Gross profit margins typically range from 65% to 80%.

The upstream supply chain of omalizumab injection mainly includes culture media and additives required for recombinant cell line construction and culture, protein purification resins and filtration consumables, disposable bioreactors and aseptic filling consumables, and packaging materials such as pre-filled glass needles or vials. The upstream supply chain has extremely high requirements for quality consistency and compliance systems. Downstream applications are the core of demand, mainly concentrated in the treatment of immune-related diseases such as severe allergic asthma and chronic spontaneous urticaria. In clinical settings, omalizumab, as an IgE-targeting biologic, is typically used for patients with insufficient response to conventional treatments, with a clear evidence-based medical foundation. It is mainly used in the respiratory, allergy, and dermatology departments of tertiary hospitals. With guideline recommendations and the accumulation of real-world data, its position in standardized long-term management is solid. In terms of payment, inclusion in medical insurance and local supplementary insurance plays a decisive role in increasing sales volume, and patient compliance and ease of administration directly affect the usage structure. Downstream customers are primarily hospitals and the medical insurance system, resulting in highly concentrated procurement, significant price negotiation, and barriers to entry.

The industrys development trend is characterized by the gradual market launch of biosimilars, driving down prices and improving accessibility. Simultaneously, optimized subcutaneous administration and an expanded patient population are contributing to structural growth. The main driving factors are the rising prevalence of allergic diseases, the promotion of standardized treatment, and expanded medical insurance coverage. Obstacles include intensified competition among biosimilars, price pressure from centralized volume-based procurement, and the substitution risk from other new mechanism biologics.

Infinity Market Research newest research report, the Omalizumab Injection Industry Forecast looks at past sales and reviews total world Omalizumab Injection sales in 2025, providing a comprehensive analysis by region and market sector of projected Omalizumab Injection sales for 2026 through 2032. With Omalizumab Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Omalizumab Injection industry.

This Insight Report provides a comprehensive analysis of the global Omalizumab Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Omalizumab Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Omalizumab Injection market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Omalizumab Injection and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Omalizumab Injection.

This report presents a comprehensive overview, market shares, and growth opportunities of Omalizumab Injection market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

    Pre-Filled Subcutaneous Injection Solution
    Lyophilized Subcutaneous Injection Solution
    Segmentation by Specifications:
    75mg
    100mg
    150mg
    Segmentation by Purity:
    More than 99.0%
    98.5%-99%
    98.0%-98.5%

Segmentation by Application:

    Allergic Asthma
    Chronic Spontaneous Urticaria (CSU)

This report also splits the market by region:

    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration.

    Novartis
    Celltrion
    Reliance
    Genentech

Key Questions Addressed in this Report

What is the 10-year outlook for the global Omalizumab Injection market?
What factors are driving Omalizumab Injection market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Omalizumab Injection market opportunities vary by end market size?
How does Omalizumab Injection break out by Type, by Application?